Nymox Pharmaceutical Corporation (NYMXF)

Nymox Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	-	0.01
Revenue Growth (YoY)	-	-	-	-	-95.69%
Cost of Revenue	-	-	-	-	0
Gross Profit	-	-	-	-	0
Selling, General & Admin	1	4.36	2.88	5.85	3.6
Research & Development	3.28	3.99	3.77	6.66	8.12
Operating Expenses	4.28	8.35	6.65	12.5	11.72
Operating Income	-4.28	-8.35	-6.65	-12.5	-11.72
Interest Expense	-0.23	-0.06	-0.04	-0.04	-0.04
Interest & Investment Income	0	0.01	0	0.01	0.03
Currency Exchange Gain (Loss)	0.02	0	0.01	-0	-0
Other Non Operating Income (Expenses)	-	-	0.11	-	-
EBT Excluding Unusual Items	-4.49	-8.4	-6.58	-12.54	-11.74
Other Unusual Items	-	-0.44	-	-	-
Pretax Income	-4.49	-8.84	-6.58	-12.54	-11.74
Net Income	-4.49	-8.84	-6.58	-12.54	-11.74
Net Income to Common	-4.49	-8.84	-6.58	-12.54	-11.74
Shares Outstanding (Basic)	94	92	89	82	74
Shares Outstanding (Diluted)	94	92	89	82	74
Shares Change (YoY)	2.16%	2.58%	9.04%	11.04%	7.23%
EPS (Basic)	-0.05	-0.10	-0.07	-0.15	-0.16
EPS (Diluted)	-0.05	-0.10	-0.07	-0.15	-0.16
Free Cash Flow	-2.6	-4.06	-5.21	-9.83	-10.05
Free Cash Flow Per Share	-0.03	-0.04	-0.06	-0.12	-0.14
Gross Margin	-	-	-	-	20.00%
Operating Margin	-	-	-	-	-234400.00%
Profit Margin	-	-	-	-	-234760.00%
Free Cash Flow Margin	-	-	-	-	-201000.00%
EBITDA	-4.28	-8.34	-6.63	-12.49	-11.71
D&A For EBITDA	0	0.01	0.03	0.01	0.01
EBIT	-4.28	-8.35	-6.65	-12.5	-11.72
Revenue as Reported	-	-	-	-	0.01

Updated Jan 2, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.